Cipla acquires brand, trademark rights for anti-diabetic drug Vysov in India

By: |
New Delhi | Published: December 16, 2019 5:10:36 PM

Cipla has been co-marketing Vildagliptin in agreement with Novartis under brand names Vysov and Vysov M (Vildagliptin plus Metformin), the company said in a regulatory filing.

cipla, cipla pharmaceuticals, cipla drug company, cipla new drug, cipla drug acquisitionThe products have witnessed a strong uptake in India for the last couple of years and are currently available across the country, the company said.

Homegrown pharma major Cipla Ltd on Monday said it has acquired brand name and trademark rights for Vysov for anti-diabetic drug Vildagliptin for the Indian market from Novartis. However, it didn’t disclose the acquisition amount. Cipla has been co-marketing Vildagliptin in agreement with Novartis under brand names Vysov and Vysov M (Vildagliptin plus Metformin), the company said in a regulatory filing.

“Owing to the increased affordability of Vildagliptin it is more accessible for better management of the disease. Cipla’s acquisition of the trademark rights of Vysov will enable us to contribute to easier access of the drug in India,” Cipla Executive Vice-President & Head India Business Nikhil Chopra said. The products have witnessed a strong uptake in India for the last couple of years and are currently available across the country, the company said.

Vildagliptin is backed by strong clinical data and is therefore a widely prescribed antidiabetic medicine for adults with type-2 diabetes mellitus, it added The market size of Vildagliptin in India is Rs 818 crore as per IQVIA MAT data of November 2019, Cipla said.

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Next Stories
1Brookfield Infrastructure Partners to invest Rs 25,215 crore in telecom tower assets of RIL
2Boeing could suspend or cut 737 MAX output: report
3Indian-Americans’ startup secures additional USD 10million investment for global rapid growth